Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Clinical trial NCT03771157 · COMPLETED

Trial details

NCT number: NCT03771157
Sponsor: University of Rochester
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia (CLL)Waldenstrom Macroglobulinemia (WM)

Start date: 2019-02-01
Primary completion: 2020-09-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.